Invited Talks
“Targeting mycobacterial cytochrome oxidases with potent small molecule inhibitors.” Mycobacteria 2026: Translating Biology into Cures, 25-26 May 2026, NTU Singapore.
“Medicinal Chemistry Odyssey.” WashU, St. Louis, MO, September 24-26, 2025.
“Advancement of Anti-TB Agents Through Academic Medicinal Chemistry.” University of British Columbia – Okanagan, Kelowna, British Columbia, Canada, October, 19, 2023.
“Lessons in Chemistry: An Academic and Industry Perspective Featuring Imidazopyridine Anti-TB Agents.” Montana State University, Bozeman, MT, February 10, 2023.
“On the Hunt for Next-Generation Antimicrobial Agents: Inhibitors of Mycobacteria Respiration.” An Online Symposium Organized Jointly by the French Society for Medicinal Chemistry (Société de Chimie Thérapeutique) and the French Microbiology Society (Société Française de Microbiologie) on 9–10 December 2021.
“Introduction to Medicinal Chemistry at MSU: Real Drugs for Real People.” BIOB 105 Introduction to Biotechnology, Montana State University, Bozeman, MT, September 2, 2021.
“Introduction to Medicinal Chemistry at MSU: Real Drugs for Real People.” BIOB 105 Introduction to Biotechnology, Montana State University, Bozeman, MT, September, 1, 2020.
“Evaluation of ND-7901 (HT-01): A fast-acting bactericidal antibacterial agent with broad activity.” Montana Biofilms Meeting, Bozeman, MT, July 8, 2020.
“Small molecule inhibitors of BD Oxidase.” Shionogi Pharmaceuticals, Osaka, Japan, Oct 29, 2019.
“Introduction to Medicinal Chemistry at MSU: Real Drugs for Real People.” BIOB 105 Introduction to Biotechnology, Montana State University, Bozeman, MT, September 6, 2019.
“Attacking M. avium.” Shionogi Pharmaceuticals, Osaka, Japan, February 14, 2018.
“Medicinal chemistry at MSU: Discovery and development of Anti-Tuberculosis Agents.” 30th Annual Fall ACS Meeting, Anaconda, MT October 6 -8, 2017.
“Introduction to Medicinal Chemistry: Real Drugs for Real People.” BIOB 105 Introduction to Biotechnology, Montana State University, Bozeman, MT, September 20, 2017.
“To Be or Not To Be—That is the Congestion Discovery and Development of ND-10885 as an Anti-Tuberculosis Treatment.” CBB Seminar Series, Montana State University, Bozeman, MT, Jan 27, 2017.
“Advancement of ND-7901 and other Clostridium difficile inhibitors.” COBRE Meeting, MSU Technology Park, November 7, 2016.
“Real Drugs for Real People.” BIOB 105 Introduction to Biotechnology, Montana State University, Bozeman, MT, October 24, 2016.
“Cats versus Grizzlies: Small molecules and their potential to inhibit biofilms.” CBE Seminar series, Montana State University, Bozeman, MT, February 17, 2016.
“Real Drugs for Real People.” BIOB 105 Introduction to Biotechnology, Montana State University, Bozeman, MT, September 16, 2015.
“Putting TB to Sleep: Advancement of Imidazo[1,2-a]pyridine Antibacterial Agents (…and Medicinal Chemistry at MSU).” CBB Seminar Series, Montana State University, Bozeman, MT, March 20, 2015.
“Imidazopyridine Anti-TB Agents: Discovery and Advancement.” Bill & Melinda Gates
Foundation, TB Drug Accelerator, Seattle, WA, February 11, 2013 via WebEx.
“Advancement of Imidazopyridine Anti-TB Agents.” Eli Lilly TB Drug Discovery Initiative, NIH, Bethesda, MD, August 12, 2012.
“Imidazopyridine as Potential Anti-TB Therapeutics.” SRI International, Menlo Park, CA,
March 19, 2012 via WebEx.
“Design and Advancement of Small Molecule Anti-TB Agents and other Surprises.” SRI International, Harrisonburg, VA, Feb. 28, 2012.
“Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.” Infectious Disease Research Institute (IDRI), Seattle, WA, Feb. 21, 2012.
“Pre-Clinical Development and Advancement of Imidazo[1,2-a]pyridine Therapeutics.” iThemba Pharmaceuticals, Cape Town, South Africa, October 10, 2011 via WebEx.
“Development and Advancement of Imidazo[1,2-a]pyridines as Anti-TB Agents.” Eli Lilly and Company Science Steering Committee, Seattle, WA, September 12, 2011.
“Advent of Imidazo[1,2-a]pyridines as new anti-TB agents.” Infectious Disease Research Institute (IDRI), Seattle, WA, August 4, 2011.
“Discovery and Evaluation of Imidazo[1,2-a]pyridines as anti-TB agents.” Institute for Tuberculosis Research (ITR), Chicago, IL, August 19, 2010.
“Recent Advances in the Miller Lab.” Miller Symposium, Notre Dame, IN, October 25, 2008.
“Not all eNotebooks are the same, a demonstration of the Chemistry Biochemistry
Interface System.” University of Notre Dame, Notre Dame, IN, Sept. 21, 2004.